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Abstract: Evidence collected over the last ten years indicates that Epac and cAMP scaffold proteins
play a critical role in integrating and transducing multiple signaling pathways at the basis of cardiac and
lung physiopathology. Some of the deleterious effects of Epac, such as cardiomyocyte hypertrophy
and arrhythmia, initially described in vitro, have been confirmed in genetically modified mice for
Epac1 and Epac2. Similar recent findings have been collected in the lung. The following sections will
describe how Epac and cAMP signalosomes in different subcellular compartments may contribute to
cardiac and lung diseases.
Keywords: cAMP; Epac; compartmentalization; A-kinase anchoring proteins; phosphodiesterases
1. Introduction
In the current manuscript, we aim to highlight the most recent insights into signaling by one
of the most ancient second messengers cyclic AMP (cAMP). We focus on novel aspects of cAMP
scaffolds maintained by a diverse subset of proteins, among them receptors, exchange proteins,
phosphodiesterases, and A-kinase anchoring proteins. We will start with the cardiac system and will
then proceed with the lung.
2. Epac in Cardiac Disease
Cyclic AMP (cAMP) is one the most important second messengers in the heart because it regulates
many physiological processes, such as cardiac contractility and relaxation. The β-adrenergic receptor
(β-AR) belongs to the G protein-coupled receptor (GPCR) superfamily, and is essential for the
adaptation of cardiac performance to physiological needs. Upon stimulation of β-AR by noradrenaline
(released from cardiac sympathetic nervous endings) and circulating adrenaline, cAMP is produced
and activates protein kinase A (PKA), which phosphorylates many of the components involved in the
excitation-coupling mechanisms, such as L-type the calcium channel (LTCC), phospholamban (PLB),
cardiac myosin binding protein C (cMyBPC), and the ryanodine receptor 2 (RyR2), to modulate their
activity [1]. Activation of LTCCs produces an inward Ca2+ current (ICa) that activates RyR2 through
the mechanism known as Ca2+-induced Ca2+ release (CICR), which raises cytosolic Ca2+ concentration
and activates contraction. Whereas PKA-dependent LTCC and RyR2 phosphorylation results in
mobilization of Ca2+ available for contraction, PKA-mediated phosphorylation of phospholamban,
a peptide inhibitor of sarcoplasmic reticulum (SR) Ca2+-ATPase promotes increased Ca2+ reuptake
in the SR, thereby removing Ca2+ from the cytoplasm and accounting for relaxation [1]. In addition,
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binding of cAMP to hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that carry
the pacemaker current, increases heart rate in response to a sympathetic stimulation (chronotropic
effect). From the three β-adrenergic subtypes expressed in the mammalian heart, regulation of cardiac
function is ascribed to the β1- and β2-adrenergic receptor subtypes [2].
Although acute stimulation of the β-AR pathway has beneficial effects on heart function,
a sustained activation of β-AR contributes to the development of pathological cardiac remodeling by
inducing ventricular hypertrophy, fibrosis, and ultimately, arrhythmia and heart failure (HF), one of
the most prevalent causes of mortality globally [3–5]. Toxic effects of sustained β-AR stimulation are
consistent with the finding that in HF patients, elevated plasma catecholamine levels correlate with the
degree of ventricular dysfunction and mortality [6]. However, β-blocker therapy in HF may appear
counterintuitive, as catecholamines represent the main trigger of cardiac contractility and relaxation.
Indeed, β-blockers restore the adrenergic signaling system which is desensitized by high and chronic
concentrations of catecholamines [3]. Thus, it is not so much to block the whole adrenergic signaling
which seems important, but rather to modulate its different aspects. It is in this context that several
research groups are interested in understanding the role of exchange proteins directly activated by
cAMP (Epac) proteins in the development of cardiac arrhythmia and HF [4].
Evidence collected over the last ten years indicates that Epac proteins play a critical role in
integrating and transducing multiple signaling pathways at the basis of cardiac physiopathology.
Some of the deleterious effects of Epac, such as cardiomyocyte hypertrophy and arrhythmia,
initially described in vitro, have been confirmed in genetically modified mice for Epac1 and Epac2.
The following sections will describe how Epac signalosomes in different subcellular compartments of
the cardiomyocyte may contribute to cardiac disease.
2.1. Epac Signalosome in Pathological Cardiac Remodeling
Given the importance of the β-AR-cAMP pathway in cardiac pathophysiology, several studies aim
to investigate the role of Epac proteins in the development of cardiac remodeling and HF. Remodeling
pathological disorder comprises multiple attacks of which the best described are the modification of the
geometry of the cardiac cavity associated with cardiomyocyte hypertrophy, fibrosis, and alterations of
calcium handling and energy metabolism [7]. In the long term, these changes affect cardiac contractility
and favor progression of HF, a process predominantly relying on cardiac signaling in response to the
β1-AR subtype.
Among the two Epac isoforms, Epac1 expression was found to be upregulated in various models
of cardiac hypertrophy, such as chronic catecholamine infusion and pressure overload induced by
thoracic aortic constriction, as well as in the end stages of human HF [8,9]. On the contrary, the
anti-hypertrophic action of some hormones and microRNA, including the growth hormone-releasing
hormone and microRNA-133, involves Epac1 inhibition [10,11]. A more direct evidence of Epac1’s
role in the regulation of cardiac remodeling came from the observation that Epac1 overexpression,
or its direct activation with the Epac1 preferential agonist, 8-pCPT-2-O-Me-cAMP (8-CPT), increased
various markers of cardiomyocyte hypertrophy, such as protein synthesis and hypertrophic genes in
primary ventricular myocytes [8,12,13]. It is hypothesized that in the setting of cardiac remodeling,
adaptive autophagy antagonizes Epac1-induced cardiac hypertrophy [14]. In vitro studies revealed
that the pharmacological inhibition of Epac1 by a tetrahydroquinoline analogue, CE3F4, prevented
the induction of cardiomyocyte hypertrophy markers in response to a prolonged β-AR stimulation in
rat ventricular myocytes [14–16]. These findings indicate that Epac1 signaling may provide a novel
means for the treatment of pathological cardiac hypertrophy. It is worth mentioning that Epac1 has
also been recently identified as a potential mediator of radiation-induced cardiomyocyte hypertrophy,
suggesting that this cAMP-sensor is involved in the side effects of anticancer therapy [17].
Compelling evidence indicates that Epac1 signalosome is highly compartmentalized and occurs
in several micro subcellular compartments, such as the plasma membrane, sarcoplasm, and the
nuclear/perinuclear region of cardiomyocytes [8,18–20]. A macromolecular complex containing the
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scaffolding protein β-arrestin, Epac1, and Ca2+/calmodulin-dependent protein kinase II (CaMKII),
has been reported in the heart [21]. Epac1 constitutively interacts with the β-arrestin in the
cytoplasm under basal conditions. Stimulation of β1-AR, but not β2-AR, induces the recruitment of
β-arrestin–Epac1 signaling complex at the plasma membrane, whereby it activates a pro-hypertrophic
signaling cascade involving the small GTPases Rap2 and Ras, and CaMKII [22]. This acts as a
trigger for histone deacetylase type 4 (HDAC4) nuclear export, which initiates a pro-hypertrophic
gene program (Figure 1). Interestingly, Epac1 is prevented from undertaking similar signaling
at the β2-AR, as the cAMP-hydrolyzing enzyme, phosphodiesterase (PDE)4D5, impedes the
interaction of Epac1 with β-arrestin, and therefore its recruitment to activated β2-AR. Of particular
importance, disruption of PDE4D5–β-arrestin complex formation with a cell-permeant peptide
promotes binding of Epac1–β-arrestin to β2-AR and, consequently β2-AR signaling switches to a
β1-AR-like pro-hypertrophic signaling to increase cardiac myocyte remodeling [22]. Taken together,
these data provide evidence that Epac compartmentalization contributes to the functional differences
between cardiac β-AR subtypes.
Besides its sarcolemma distribution, Epac1 is also concentrated in the nuclear/perinuclear region
of cardiomyocytes, positioned well to regulate nuclear signaling [8,20]. Specifically, it was shown that
Epac1 is scaffolded at the nuclear envelope with phospholipase C (PLC)ε and muscle-specific A-kinase
anchoring proteins (AKAPs) to regulate the hypertrophic gene program in primary cardiomyocytes [19,23,24]
(Figure 1). Interestingly, a detailed analysis of Ca2+ mobilization in different microdomains demonstrated
that Epac (probably Epac1) preferentially elevated Ca2+ in the nucleoplasm, correlating with the
perinuclear/nuclear localization of Epac1 [25]. Additional in vitro studies showed that Epac1, via its
downstream effector, the small G protein Rap2, activated PLC to promote the production of inositol
1,4,5-trisphosphate (IP3) [26]. Based on this finding, a working hypothesis has been proposed, whereby
Epac1 can activate PLC, causing nuclear Ca2+ increase via perinuclear IP3 receptor (IP3-R), which
results in the activation of Ca2+-dependent transcription factors involved in cardiac remodeling [25,27]
(Figure 1). Consistently, in cultured cardiomyocytes, it has been reported that Epac activates CaMKII
to induce the nuclear export of HDAC4 de-repressing the transcription factor myocyte enhancer
factor 2 (MEF2) which activates gene transcription, essential for the hypertrophic program [25,26].
Collectively, these findings point to Epac1 role in activating the excitation–transcription coupling,
the process by which Ca2+ activates gene transcription [27]. Additional Epac hypertrophic signaling
have been described and include the GTPase H-Ras, the Ca2+ sensitive protein, calcineurin, and its
downstream effector, nuclear factor of activated T cells (NFAT), which are key mediators of cardiac
remodeling [8,26].
More recently, the study of Epac gene deleted mice has made it possible to better understand the
role of these proteins in cardiac pathological remodeling. Global knockout (KO) mice for Epac1 or
Epac2, or double full KO for Epac1 and Epac2, do not present any cardiac abnormality, suggesting
that these guanine-nucleotide exchange factors activated by cyclic adenosine monophosphate
(cAMP-GEFs) do not play a major role during cardiac development [14,28,29]. None of the deletions
appreciably affected basal cardiac function. Although Epac has been shown to influence myofilament
Ca2+ sensitivity in rat cardiomyocytes [18,30], the effects of Epac activation in cell contractility
remain controversial, and may depend on the steady-state Ca2+ levels at which the myocyte is
functioning [18,31–33]. Overall, Epac proteins do not play a major role in the physiological regulation
of cardiomyocyte contractility in response to acute β-AR stimulation, compared with PKA, which
is the main cAMP effector in this process [29,34]. However, Epac1 genetic inhibition specifically
reduces cardiac remodeling induced by chronic activation of β-AR, which confirms the importance of
Epac1 in the β-adrenergic signaling during cardiac stress condition [14,28]. Moreover, Epac1 deleted
cardiomyocytes prevented 8-CPT-dependent HDAC5 translocation, consistent with its involvement in
pathological hypertrophy [20]. Of note, in another model of cardiac hypertrophy induced by aortic
stenosis, Epac1 knockdown fails to prevent cardiac hypertrophy, but only fibrosis and cardiomyocyte
J. Cardiovasc. Dev. Dis. 2018, 5, 50 4 of 16
apoptosis, suggesting that the cardioprotective effects of Epac1 deletion with respect to hypertrophy
depend on the nature of stress [19].
J. Cardiovasc. Dev. Dis. 2018, 5, x FOR PEER REVIEW  3 of 17 
 
scaffolding protein β-arrestin, Epac1, and Ca2+/calmodulin-dependent protein kinase II (CaMKII), has 
been reported in the heart [21]. Epac1 constitutively interacts with the β-arrestin in the cytoplasm 
under basal conditions. Stimulation of β1-AR, but not β2-AR, induces the recruitment of β-arrestin–
Epac1 signaling complex at the plasma membrane, whereby it activates a pro-hypertrophic signaling 
cascade involving the small GTPases Rap2 and Ras, and CaMKII [22]. This acts as a trigger for histone 
deacetylase type 4 (HDAC4) nuclear export, which initiates a pro-hypertrophic gene program (Figure 
1). Interestingly, Epac1 is prevented from undertaking similar signaling at the β2-AR, as the cAMP-
hydrolyzing enzyme, phosphodiesterase (PDE)4D5, impedes the interaction of Epac1 with β-arrestin, 
and therefore its recruitment to activated β2-AR. Of particular importance, disruption of PDE4D5–β-
arrestin complex formation with a cell-permeant peptide promotes binding of Epac1–β-arrestin to β2-
AR and, consequently β2-AR signaling switches to a β1-AR-like pro-hypertrophic signaling to 
increase cardiac myocyte remodeling [22]. Taken together, thes  data provide evidence that Epac 
compartmentalization contributes to the functional differences between cardiac β-AR subtypes. 
 
Figure 1. Epac signalosome in cardiac hypertrophy and ischemia. Under adrenergic stimulation, the 
Epac1–β-arrestin complex is recruited at the β1-AR, and activates a pro-hypertrophic signaling 
pathway. Epac1 is also scaffolded at the nuclear envelope with phospholipase C (PLC)ε and muscle-
specific A-kinase anchoring proteins (mAKAP) to regulate the hypertrophic gene program. In the 
nuclear/perinuclear region, PLCε increases nuclear Ca2+ content via the activation of the perinuclear 
IP3 receptor (IP3-R). Epac1 hypertrophic signaling also involves CaMKII-dependent phosphorylation 
of RyR2, leading to Ca2+ leak from the sarcoplasmic reticulum and subsequent calcineurin (CaN) 
activation. The anti-hypertrophic action of the growth hormone-releasing hormone (GHRH) or its 
agonistic analog, MR-409, involves the protein kinase A (PKA)-dependent inhibition of Epac1 
expression. MicroRNA-133 (miR-133) is cardioprotective, and targets several components of β1-AR 
signaling. In the context of cardiac ischemia, mitochondrial Epac1 (MitEpac1) is activated by cAMP 
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cyclase; CaMKIIδ, Ca2+/calmodulin-dependent protein kinase II δ-isoform; cAMP, cyclic adenosine 
monophosphate; DAG, diacylglycerol; GHRH-R, GHRH receptor; GRP75, chaperone glucose-
regulated protein 75; HDAC4, histone deacetylase 4; IDH2, isocitrate dehydrogenase 2; IP3, inositol-
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Figure 1. Epac signalosome in cardiac hypertrophy and ischemia. Under adrenergic stimulation,
the Epac1–β-arrestin complex is recruited at the β1-AR, and activates a pro-hypertrophic signaling
pathway. Epac1 is also scaffolded at the nuclear envelope with phospholipase C (PLC)ε and
muscle-specific A-kinase anchoring proteins (mAKAP) to regulate the hypertrophic gene program.
In the nuclear/perinuclear region, PLCε increases nuclear Ca2+ content via the activation of the
perinuclear IP3 receptor (IP3-R). Epac1 hypertrophic signaling also involves CaMKII-dependent
phosphorylation of RyR2, leading to Ca2+ leak from the sarcoplasmic reticulum and subsequent
calcineurin (CaN) activation. The anti-hypertrophic action of the growth hormone-releasing hormone
(GHRH) or its agonistic analog, MR-409, involves the protein kinase A (PKA)-dependent inhibition of
Epac1 expression. MicroRNA-133 (miR-133) is cardioprotective, and targets several components of
β1-AR signaling. In the context of cardiac ischemia, mitochondrial Epac1 (MitEpac1) is activated
by cAMP produced by the soluble adenylyl cyclase (sAC), and increases Ca2+ overload and
ROS accumulation to promote mitochondrial permeability transition pore (MPTP) opening and
cardiomyocyte apoptosis. α-KG,α-ketoglutarate; β1-AR, β1-adrenergic receptor; AC, transmembrane
adenylyl cyclase; CaMKIIδ, Ca2+/calmodulin-dependent protein kinase II δ-isoform; cAMP, cyclic
adenosine monophosphate; DAG, diacylglycerol; GHRH-R, GHRH receptor; GRP75, chaperone
glucose-regulated protein 75; HDAC4, histone deacetylase 4; IDH2, isocitrate dehydrogenase 2;
IP3, inositol-1,4,5-trisphosphate; IP3R1, IP3 receptor 1; IP3R1, inositol-1,4,5-triphosphate receptor 1;
MEF2, myocyte enhancer factor-2; NFAT, nuclear factor of activated T-cells; PIP2, phosphatidylinositol
4,5-biphosphate; ROS, reactive oxygen species; Ser, serine; TCA, tricarboxylic acid cycle; VDAC1,
voltage-dependent anion channel 1.
2.2. Role of Epac in Heart Failure and Arrhythmia
Interestingly, Epac1 KO mice show better cardiac contractility (maintenance of the inotropic
reserve) and decreased susceptibility to HF in response to different hypertrophic stress conditions
(catecholamine infusion or myocardial pressure overload) [14,28]. Further evidence for the
cardioprotective effect of Epac1 inhibition came from the recent report that Epac1 deficiency attenuates
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type 5 adenylyl cyclase-mediated catecholamine stress-induced cardiac dysfunction [35]. It is
interesting to note that Epac1 and Epac2 deleted mice are protected from the incidence of atrial
and ventricular arrhythmia, respectively, suggesting a specific role of Epac isoforms in cardiac rhythm
disorders [28,29]. Conversely, direct pharmacological activation of Epac with the cAMP analogue 8-CPT
promotes ventricular arrhythmogenesis in isolated perfused mouse hearts [36]. Such arrhythmogenic
features were also observed in rat cardiomyocytes, but after sustained Epac activation [37]. Yet, Brette
and colleagues reported that 8-CPT induced an action potential lengthening in rat ventricular myocytes,
a process involved in the genesis of arrhythmia by predisposing cardiac myocytes to early after
depolarizations and dispersion of repolarization [38].
Mechanistically, few studies demonstrated that mainly Epac1 regulated the expression level
of proarrhythmic channels, such as the slow delayed-rectifier potassium K+-current (IKs) subunit
potassium voltage-gated channel and transient receptor potential canonical 3 and 4 channels that
enhance store-operated Ca2+ entry [39,40] (Figure 2). Epac function may also affect susceptibility to
arrhythmia via the regulation of gap junction formation [41,42]. Importantly, in isolated ventricular
myocytes, activation of Epac with either 8-CPT or β1-AR induces a spontaneous release of Ca2+ from
the SR (a process named Ca2+ sparks) via the CaMKII-dependent phosphorylation of RyR2 on Serine
2814 or 2815 (depending on the species), thereby causing diastolic Ca2+ leak in a PKA-independent
manner [29,31–33,43] (Figure 2). Consistent with the localization of Epac2 along T tubules in mouse
cardiomyocytes [20], it has been proposed that the increase of ectopic release of Ca2+ following
Epac2 (and not Epac1) activation by β1-AR, could be the cause of arrhythmogenic effects in
cardiomyocytes [29]. The recent finding that SR Ca2+ leak observed upon PDE4 inhibition involves
Epac2 suggests that the interaction of PDE4 and Epac2 are critical for coordinating the pro-arrhythmic
effect of cAMP [34]. Adding complexity to the matter, another study showed that Epac1 promoted PLB
hyperphosphorylation on Serine 16 via PKCε [28]. This could lead to SR Ca2+ overload with Ca2+ leak
and subsequent arrhythmia [28] (Figure 2). Based on the aforementioned studies, the beneficial effect of
Epac inhibition seems, therefore, very attractive for the development of novel therapies against HF and
arrhythmia. However, few controversies have been reported in the literature. Among them, Yang and
colleagues recently reported that pharmacological inhibition of Epac2 with ESI-05 was proarrhythmic
in rat [44]. Further pharmacological and genetic studies combining the use of Epac isoform-specific
ligands and conditional Epac KO mice are required to better decipher the role of Epac isoforms in
cardiac rhythm disorders.
2.3. Role of Mitochondrial Epac in Cardiac Ischemia
Acute myocardial infarction is a leading cause of mortality and morbidity worldwide. Early coronary
reperfusion has been established as the best therapeutic strategy to limit infarct size and improve
prognosis. However, the process of reperfusion can itself induce cardiomyocyte death, known as
myocardial reperfusion injury (I/R), for which there is still no effective therapy [45,46]. Mitochondria
have been recognized as playing a central role in both apoptotic and necrotic cell death [47]. Indeed,
during I/R injury, cardiomyocyte death is initiated by mitochondrial Ca2+ overload and an excessive
production of reactive oxygen species (ROS) which trigger the mitochondrial permeability transition
pore (MPTP) opening, resulting in mitochondrial depolarization, swelling, and rupture of the external
mitochondrial membrane. This leads to the uncoupling of the respiratory chain, and the efflux of
cytochrome c and other proapoptotic factors that may induce apoptosis or necrosis [48].
Depending on the nature of the stimulus and the cell type used in the study, Epac may play a
proapoptotic or antiapoptotic role [49]. For instance, in neonatal rat cardiomyocytes, Epac cooperates
with PKA in the antiapoptotic effects of exendin-4, a glucagon-like peptide-1 receptor agonist [50].
Similarly, activation of both PKA and Epac with cAMP analogues confers cardioprotection against I/R
injury in isolated rat heart [51]. Interestingly, it is suggested that long-term feeding of an obesogenic
high fat diet renders the myocardium less susceptible to I/R induced injury via Epac-dependent
signaling [52]. Yet, recent findings using isolated cardiomyocytes from ischemic rat hearts have
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implied that the cardioprotective effect induced by urocortin-1 involved the Epac2 pathway [53].
On the contrary, in vivo experiments showed that Epac1 genetic ablation in mice protected against
myocardial I/R injury with reduced infarct size and cardiomyocyte apoptosis [54]. Consistent with an
earlier finding showing the mitochondrial expression of transfected Epac1 in COS-7 cells [55], Epac1
is expressed in the mitochondrial inner membrane and matrix of cardiomyocytes. A form of Epac1
deleted in its mitochondrial-targeting sequence protects against hypoxia/reoxygenation (a condition
mimicking in vivo I/R)-induced cell death, indicating that mitochondrial Epac1 participates in
cardiomyocyte death during hypoxic stress [54]. Mechanistic studies demonstrated that during
hypoxia/reoxygenation, Epac1 was activated by the type 10 soluble adenylyl cyclase (sAC) to increase
mitochondrial Ca2+ uptake and ROS production, thereby promoting mitochondrial death signaling,
such as MPTP opening, cytochrome c release, and both caspase-9 and -3 activation [54]. However,
these results are not in agreement with another study, which reported that direct activation of sAC
with HCO3− prevented Ca2+-induced MPTP opening through Epac1, suggesting that Epac1 might
protect from cardiomyocyte death [56]. The higher amount of cAMP produced in the model of
hypoxia/reoxygenation, and subsequent massive increase in mitochondrial ROS and Ca2+ levels,
could potentially account for the observed differences.
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Figure 2. Role of Epac in cardiac arrhythmia. Epac proteins increase the phosphorylation state of the
ryanodine receptor 2 (RyR2) via CaMKII, and subsequent Ca2+ leak from the sarcoplasmic reticulum
(SR) may trigger arrhythmia. Epac1-induced hyperphosphorylation of phospholamban (PLB) may
also contribute to the development of arrhythmia and heart failure. In addition, Epac enhances
store-operated Ca2+ entry (SOCE)-like activity, which is related to an increased amount of functional
transient receptor potential canonical (TRPC) 3 (TRCP3) and TRCP4 channels. This additional Ca2+
entry pathway in the cardiomyocyte and the downregulation of the potassium voltage-gated channel
subfamily E member 1 (KCNE1) participate in the proarrhythmic effect of Epac proteins. β1-AR,
β1-adrenergic receptor; AC, transmembrane adenylyl cyclase; CaMKII, Ca2+/calmodulin-dependent
protein kinase II; cAMP, cyclic adenosine monophosphate; CaN, Calcineurin; DAG, diacylglycerol; IP3,
inositol-1,4,5-trisphosphate; P, phosphorylation; PDE4, phosphodiesterase 4; PIP2, phosphatidylinositol
4,5-biphosphate; PKCε, protein kinase C epsilon type; PLB, phospholamban; PLCε, phospholipase C
epsilon type; SERCA, sarcoendoplasmic reticulum calcium transport ATPase.
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Interestingly, we found that Epac1 is highly compartmentalized in mitochondria and targets
key proteins involved in mitochondrial Ca2+ uptake and ROS production. Indeed, firstly, we
revealed that Epac1 interrelated with a macromolecular complex composed of the VDAC1 (voltage-
dependent anion channel 1), the GRP75 (chaperone glucose-regulated protein 75), and the IP3R1
(inositol-1,4,5-triphosphate receptor 1). This complex localized at the endoplasmic reticulum (ER)
junction is considered as a hot spot from Ca2+ transfer from the ER to the mitochondria [57]. Under
hypoxic condition, Epac1 activation increased the interaction with the VDAC1/GRP75/IP3R1 complex,
hence facilitating ER to mitochondrial Ca2+ transfer. Epac1-mediated mitochondrial Ca2+ overload
subsequently provoked MPTP opening, cytochrome c release, and ultimately, cardiomyocyte death [54]
(Figure 1). Secondly, our study revealed a key role for Epac1 in the accumulation of mitochondrial
ROS production during hypoxia. Surprisingly, we observed that Epac1 imported CaMKII into matrix
where they formed a multi-molecular complex with isocitrate dehydrogenase 2 (IDH2), a critical
mitochondrial enzyme of the tricarboxylic acid (TCA) cycle involved in ROS detoxification [54].
Mitochondrial Epac1 negatively regulates via the CaMKIIδ-dependent phosphorylation activity of
IDH2, and hence, decreases the antioxidant capabilities of the cardiomyocytes during I/R [54] (Figure 1).
Altogether, these findings identify Epac1 as a central mechanism for mitochondrial Ca2+ entry and
ROS production in myocardial cell death, and indicate that mitochondrial-targeted Epac1 inhibition
could prevent or reduce myocardial death in the setting of cardiac ischemia.
3. Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is one major health problem known to increase
morbidity and mortality all over the world. It is predicted that COPD will become the third leading
cause of death (~8.3 million), and the third leading cause of death by disability until 2030 [58]. Globally,
exposure to cigarette smoke (CS) is considered to be the primary cause for COPD. Inhalation of CS
causes the release of different cytokines, chemokines, and lipid mediators (such as tumor necrosis
factor-α (TNF-α), interleukin 8 (IL-8), transforming growth factor-β (TGF-β) and leukotriene B4) from
resident cells in the lung including epithelial cells and alveolar macrophages. Subsequently, these
mediators activate inflammatory cells which release large amounts of proteases, including elastase
and matrix metalloproteinases (MMPs), into the matrix compartment, thereby triggering the complex
process of remodeling, thus leading to obstruction of small airways, emphysema, with enlargement of
air spaces and destruction of lung parenchyma, loss of lung elasticity, and closure of small airways,
fibrosis, inflammation, mucus hyper-secretion, and pulmonary hypertension. Furthermore, more and
more evidence indicates that CS exposure also provokes an oxidant/antioxidant imbalance, which
in turn will subsequently induce COPD exacerbations [59,60]. Therefore, the most effective way to
prevent the development of COPD is smoke cessation [61,62]. Additionally, other factors including
exposure to indoor air pollutions from biomass fuels, particularly in developing countries, occupational
dusts, chemicals, and genetics, may also contribute toward disease morbidity and mortality [63,64].
Currently, the pharmacological management of COPD mainly relies on bronchodilator therapy, mainly
β2-agonists and anticholinergics, by activating different signaling pathways [65–68]. β2-Agonists
induce airway smooth muscle (ASM) cell relaxation through enhanced intracellular cAMP production,
whereas anticholinergics or antimuscarinic drugs antagonize muscarinic receptors (M1, M2 and
M3) to a certain extent, thus inhibiting ASM contraction, due to the reduction of intracellular Ca2+.
PDE4 inhibitors, which mediates cAMP breakdown (see below), are also approved to be used as
an add-on treatment for severe COPD patients associated with bronchitis and a history of frequent
exacerbations [69]. In addition, anti-inflammatory drugs, such as inhaled glucocorticosteroids, are
often used, mainly in patients with frequent exacerbations [70].
3.1. Compartmentalization of cAMP in the Lung
The production of cAMP is initiated by the stimulation of Gs-coupled receptors, such as the β-AR
and distinct subset of prostanoid receptors [71]. After receptor ligand binding, ACs are activated by the
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α subunit of the Gs-protein, thus resulting in cAMP synthesis from adenosine triphosphate (ATP) [72].
Intracellular cAMP levels are tightly controlled by cyclic nucleotide PDEs, which hydrolyze cAMP
to 5′-AMP, and thereby terminate its signaling [73]. Membrane clustering of Gs-coupled receptors
ACs and PDEs, which are localized in lipid rafts and caveolae, together with cAMP downstream
effectors, such as cAMP-gated ion channels, PKA, and Epac, dynamically regulate intracellular cAMP
signaling in the lung, including airway relaxation [74,75], reduction of inflammation [76–79], and
fibrosis [77,80]. In addition, AKAPs bind directly to PKA and its targeted proteins, and physically
tether these multi-protein complexes to specific locations, generating spatiotemporal discrete signaling
complexes [81,82], and subsequently controlling specific cellular responses (Figure 3).
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PDE4A4 was significantly upregulated not only in lung macrophages from COPD patients, but also
in peripheral blood monocytes of smokers, together with PDE4B2 [84]. In isolated peripheral blood
neutrophils, significantly higher PDE4B and PDE4D, but not PDE4A or PDE4C, mRNA levels could
be observed in the COPD patients compared to healthy subjects. Yoon et al. reported the association
of a novel PDE4D single nucleotide polymorphism (rs16878037) with COPD from a genome-wide
association study [85]. PDE4 is also of importance in other pulmonary diseases, such as asthma.
It was shown by Trian et al. that β-agonist isoproterenol-induced cAMP production in asthmatics
ASM cells was dramatically decreased due to increased PDE4D expression, rather than an alteration
in PDE3A or PDE5A expression [86]. Furthermore, CS, as the primary cause for COPD, was also
proven to increase PDE4 isoforms’ expression and activity in different experimental settings. Higher
PDE4B and PDE4D mRNA levels could be detected after 6 h CS extract exposure in isolated peripheral
blood neutrophils [87]. Exposure with CS extract for 24 h upregulated PDE4 activity in differentiated
bronchial epithelial cells, with a markedly increased mRNA transcripts for PDE4B, while increments
in PDE4A and D transcripts remained below significance [88].
Other PDE family members also attracted the attention of researchers, such as PDE7, which is
encoded by PDE7A and PDE7B. PDE7B is expressed predominantly in brain, heart, and liver, but not in
lung [89,90]. However, PDE7A, which is widely expressed in airway structural cells, including airway
epithelial cells [91], ASM cells and lung fibroblast, and also human proinflammatory and immune
cells [92], has particularly drawn attention in the treatment of COPD [93]. It has been shown that the
protein expression of PDE7A1 is significantly increased in human monocytes during cell aging [94].
In addition, PDE3A is upregulated in human endobronchial biopsies obtained from patients with
asthma, indicating that PDE3 is also involved in the pathogenesis of lung diseases.
3.3. AKAPs in COPD
As one of the most vital pharmaceutical targets in COPD, β2-AR directly interacts with AKAP5
and AKAP12, which modulate either the downstream extracellular signal-regulated protein kinase
(ERK)1/2 activation or receptor resensitization [81,94–96]. Therefore, it is believed that AKAP5 and
AKAP12 play a pivotal role in modulating the effect of β2-agonists on COPD pathological development.
Poppinga et al. showed that less AKAP5 and AKAP12 proteins could be detected in CS-exposed
ASM cells, which was also confirmed using lung tissues from COPD patients [97]. Moreover, st-Ht31,
which disrupts global AKAP–PKA interactions (see Figure 3), increased the IL-8 secretion induced
by CS exposure in human ASM cells, and reduced the suppression of β2-agonist fenoterol through
disturbed ERK signaling [97]. On the contrary, AKAP5 and AKAP12 expression were not significantly
changed by CS in human bronchial epithelial cells [98], indicating a different regulatory pathway
involved other AKAP members in epithelial cells (Figure 3). Indeed, it has been demonstrated that
AKAP9, which binds and regulates ACs [99,100], was able to maintain epithelial barrier function [99]
(Figure 3). In addition, as a major site for energy generation and reactive oxygen species (ROS)
production, mitochondria cAMP compartments was regulated by a set of mitochondrial AKAPs.
In particular, AKAP121, tethering PKA to the outer wall of mitochondria, play a pivotal role in
mitochondrial function maintenance and keeping the tolerance to oxidative stress in vascular smooth
muscle cells [101], indicating a potential protective effect on CS-induced ROS production for future
studies (Figure 3).
3.4. Epac in COPD
In addition to PKA, as mentioned earlier, Epac is another downstream effector for cAMP [102].
Epac, which is able to be activated by PKA or cAMP in both a PKA-dependent and -independent
manner, has been proven to associate with diverse effectors, thus contributing to numerous cellular
processes, including airway relaxation, cytokine secretion, barrier function, cell proliferation, migration,
and protein translocation in the lung. Also, it has been demonstrated by Scott et al. that Epac
activation by 8-CPT could reverse neutrophils’ phagocytic impairment induced experimentally by
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using β2-agonists, without interfering with RhoA activity [103]. In addition, Epac activation by 8-CPT
changed methacholine-induced myosin light chain (MLC) phosphorylation in ASM cells, skewing the
balance between RhoA and Rac1 towards Rac1, and thus reducing the phosphorylation of MLC; a
process leading to ASM relaxation [75]. In addition, pharmacological activation of Epac attenuated CS
extract-induced IL-8 release from human ASM cells by activating the NF-κB inhibitory protein IκBα and
inhibiting p65 nuclear translocation, underling the inhibitory effect of Epac on NF-κB activation [104].
Two isoforms, Epac1 and Epac2, are expressed in most lung cell types, among them, ASM, epithelial
cells, fibroblasts, and some immune cells [103,105]. Intriguingly, a selective downregulation of Epac1,
rather than Epac2, expression was observed in both CS-exposed ASM cells and lung tissue from COPD
patients, pointing to distinct intracellular functions and locations of Epac1 and Epac2 [104]. It was
further demonstrated that the upregulation of miRNA7 expression in COPD patients was linked to the
downregulation of Epac1 [106]. Moreover, the role of Epac1 and Epac2 was further investigated in
Epac1(−/−) and Epac2(−/−) mice using an acute and short-term CS exposure model. Compared to
wild type mice exposed to CS, Epac1(−/−) mice showed increased MUC5AC and matrix remodeling
parameters (TGF-β, collagen I, and fibronectin) in the lung homogenates, however, Epac2(−/−) mice
had lower amount of inflammatory cells (total inflammatory cells, macrophages, and neutrophils)
in the bronchoalveolar lavage fluid, suggesting that Epac1 was able to inhibit remodeling process,
whereas Epac2 primarily increased inflammatory processes [107]. These differences between Epac1
and Epac2 indicate compartmentalized cAMP signaling in the lung, which needs to be further studied
in the future.
4. Conclusions and Future Perspectives
Evidence collected over the last decade indicates that Epac and the cAMP signalosome substantially
contribute to the development and progression of heart and obstructive lung disorders, as exemplified
here by studies focusing on COPD. Traditionally, research focused on PKA as one of the main targets
of cAMP. However, recent studies indicated that next to classical signaling pathways, there seem to be
substantial role for additional cAMP targets, such as Epac, and for the theme of compartmentalized
cAMP signaling. The latter topic involves next to cAMP-elevating receptors (for example the β-ARs),
cAMP-producing adenylyl cyclase and cAMP-degrading PDEs, a subset of AKAPs. Particularly,
studies on the levels of Epac and PDEs benefit from the recent development of pharmacological
tools [13,19,108], suggesting that the therapeutic arsenal to treat chronic disorders of the heart and the
lung will be substantially improved in the next decades. Unfortunately, the research on compartments
being stabilized and maintained by members of the AKAP superfamily still lacks the development of
subtype specific modulators, which will hopefully be the focus of future studies.
In the heart, research over the last years has shown that particularly Epac1 seems to act
cardioprotectively with regard to cardiac fibrosis and apoptosis, but that the role of Epac1 seems
to be rather distinct, and being largely dependent on the nature of the stress inducer. Such findings
nicely reflect the fact that our aging world population requires a vast majority of novel personalized
medicine-based drugs [19,71,109]. Distinct roles of Epac1 and Epac2 seemed to emerge in the field of
heart failure and arrhythmia, as well as cardiac ischemia. Here, interaction of Epac with members
of the AKAP family or PDE subtype, such as PDE4, seem to be leading next to a defined subcellular
targeting of Epacs to defined compartments, such as the nucleus and mitochondria. In the lung, it
seemed to be that PDEs are crucially involved in the compartmentalization of cAMP next to members
of the AKAP family and Epac. Interestingly, it seemed to be that subtypes of PDEs guide cAMP
properties in a rather response-specific manner, such as anti-inflammation and bronchodilation. Novel
anti-inflammatory drugs are urgently required, as under disease conditions being characterized by
an overload of ROS, the golden treatment standard, glucocorticosteroids, are ineffective. Most likely,
compartment-specific mode of actions of PDEs are supported by AKAPs and Epac. Future studies
should focus on unravelling compartmentalized signaling cues in the heart and lung.
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